Sun Pharma’s specialty portfolio, Organon deal to drive growth

Sun Pharmaceutical achieved notable revenue growth in the September quarter, driven by strong performance in India and specialty medicines. The company anticipates medium-term growth from therapies like Ilumya and ongoing innovative projects. Although profitability was affected by acquisition and…

Khabar Adda curates headlines like this across Top Stories, Entertainment, Bollywood, Hollywood, Crime and Politics from public RSS feeds. This page links out to economictimes.indiatimes.com's own reporting rather than reproducing it — the excerpt above comes from economictimes.indiatimes.com's own feed.